nach oben

Clinical & Experimental Metastasis

Erschienen in:

01.08.2015 | Research Paper

Targeting Notch signaling by γ-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer

verfasst von: Hyun-Woo Lee, Seok-Jun Kim, Il Ju Choi, Jaewhan Song, Kyung-Hee Chun

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Current medication for gastric cancer patients has a low success rate and the patients develop rapid tolerance to these drugs. Therefore, the development of new regimens is desired. In this study, we determined that Notch-signaling-related genes were overexpressed and activated in gastric cancer patients and gastric cancer cell lines. According to recent studies, γ-secretase inhibitors (GSIs), which function as Notch signaling inhibitors, could be used as therapeutic drugs in cancer. We demonstrated that GSI I (cbz-IL-CHO) is the most effective GSI in gastric cancer cells. We also determined the cell survival signaling-related proteins that were affected by GSI I. The levels of phosphorylated AKT were significantly decreased upon GSI I treatment, and constitutively activated myristoylated AKT completely blocked GSI I-induced apoptosis and cell survival, suggesting that inhibition of AKT signaling is critical for GSI I-mediated effects in gastric cancer cells. In order to maximize the effects and safety of GSI I, a combination treatment with GSI I and 5-FU was performed. Inhibition of gastric cancer cell proliferation with the combination treatment was significantly better than that with the single treatment. All phosphorylated forms of AKT, p44/42, JNK, and p38 were drastically changed by the combination treatment. Orthotopically transplanted gastric tumor burdens in mice were reduced using the combined treatment. The outcomes of this study clearly demonstrated the therapeutic potential of GSI I in gastric cancer, as well as the greater efficacy of the combined treatment of GSI I with 5-FU. Therefore, we suggest that further clinical trials examining the potential of combined GSI I and 5-FU treatment in gastric cancer patients be undertaken.

Nur mit Berechtigung zugänglich

De Vita F et al (2012) Current status of targeted therapies in advanced gastric cancer. Expert Opin Ther Targets 16(Suppl 2):S29–S34PubMedCrossRef

Satoh T, Sakata Y (2012) S-1 for the treatment of gastrointestinal cancer. Expert Opin Pharmacother 13(13):1943–1959PubMedCrossRef

Ajani JA et al (2007) Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 study group. J Clin Oncol 25(22):3205PubMedCrossRef

Dreesen O, Brivanlou AH (2007) Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev 3(1):7–17PubMedCrossRef

Knowlton AA (2006) NFkappaB, heat shock proteins, HSF-1, and inflammation. Cardiovasc Res 69(1):7–8PubMedCrossRef

Mivechi NF et al (1994) Analysis of HSF-1 phosphorylation in A549 cells treated with a variety of stresses. Int J Hyperth 10(3):371–379CrossRef

Dickson BC et al (2007) High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol 20(6):685–693PubMedCrossRef

Park JT et al (2006) Notch3 gene amplification in ovarian cancer. Cancer Res 66(12):6312–6318PubMedCrossRef

O’Neil J et al (2006) Activating notch1 mutations in mouse models of T-ALL. Blood 107(2):781–785PubMedCentralPubMedCrossRef

10.

Shih I-M, Wang T-L (2007) Notch signaling, γ-secretase inhibitors, and cancer therapy. Cancer Res 67(5):1879–1882PubMedCrossRef

11.

Curry CL et al (2005) Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi’s sarcoma tumor cells. Oncogene 24(42):6333–6344PubMed

12.

Zhang Y et al (2001) Heat shock factor-4 (HSF-4a) is a repressor of HSF-1 mediated transcription. J Cell Biochem 82(4):692–703PubMedCrossRef

13.

Wong GTMD, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJ, Zhang L, Higgins GA, Parker EM (2004) Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279:12876–12882PubMedCrossRef

14.

Vaisman N, Evgen’ev MB, Golubovskii MD (2012) [Parallelism and paradoxes on viability and the life span of two loss-of-function mutations: heat shock protein transcriptional regulator hsf (1) and l (2) gl tumor suppressor in D. melanogaster]. Izvestiia Akademii Nauk Seriia biologicheskaia/Rossiiskaia Akademiia Nauk 1:27–34PubMed

15.

Kim SJ et al (2014) Up-regulation of neogenin-1 increases cell proliferation and motility in gastric cancer. Oncotarget 5(10):3386–3398PubMedCentralPubMed

16.

Kim SJ et al (2012) MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7. Breast Cancer Res 14(1):R14PubMedCentralPubMedCrossRef

17.

Kim SJ et al (2013) Galectin-7 is epigenetically-regulated tumor suppressor in gastric cancer. Oncotarget 4(9):1461PubMedCentralPubMed

18.

Lee HW, Jang KS, Chun KH (2014) Celastrol inhibits gastric cancer growth by induction of apoptosis and autophagy. BMB Rep 47(12):697PubMedCentralPubMedCrossRef

19.

Cheong TC, Shin JY, Chun KH (2010) Silencing of galectin-3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemotherapeutic agents. Cancer Sci 101(1):94–102PubMedCrossRef

20.

Choi SW et al (2015) Glucose deprivation triggers protein kinase C-dependent beta-catenin proteasomal degradation. J Biol Chem 290(15):9863–9873PubMedCentralPubMedCrossRef

21.

Ahn YH et al (2012) STAT3 silencing enhances the efficacy of the HSV.tk suicide gene in gastrointestinal cancer therapy. Clin Exp Metastasis 29(4):359–369PubMedCrossRef

22.

Kim SJ et al (2014) Ablation of galectin-3 induces p27(KIP1)-dependent premature senescence without oncogenic stress. Cell Death Differ 21(11):1769–1779PubMedCentralPubMedCrossRef

23.

Wang YG et al (2012) Galectin-3 increases the motility of mouse melanoma cells by regulating matrix metalloproteinase-1 expression. Exp Mol Med 44(6):387–393PubMedCentralPubMedCrossRef

24.

Cho Y et al (2015) Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancer. Oncotarget 6(11):8709–8721PubMedCentralPubMed

25.

Baek JH et al (2014) Galectin-3 activates PPARgamma and supports white adipose tissue formation and high-fat diet-induced obesity. Endocrinology 156(1):147–156CrossRef

26.

Kim SJ et al (2011) Development of microRNA-145 for therapeutic application in breast cancer. J Control Release 155(3):427–434PubMedCrossRef

27.

Ko A et al (2012) Acceleration of gastric tumorigenesis through MKRN1-mediated posttranslational regulation of p14ARF. J Natl Cancer Inst 104(21):1660–1672PubMedCentralPubMedCrossRef

28.

Palomero T, Dominguez M, Ferrando AA (2008) The role of the PTEN/AKT pathway in NOTCH1-induced leukemia. Cell Cycle 7(8):965–970PubMedCentralPubMedCrossRef

29.

Palomero T, Ferrando A (2008) Oncogenic NOTCH1 control of MYC and PI3 K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas. Clin Cancer Res 14(17):5314–5317PubMedCentralPubMedCrossRef

30.

Yeh TS et al (2009) The activated notch1 signal pathway is associated with gastric cancer progression through cyclooxygenase-2. Cancer Res 69(12):5039–5048PubMedCrossRef

31.

Miele L (2006) Notch signaling. Clin Cancer Res 12(4):1074–1079PubMedCrossRef

32.

Reedijk MOS, Chang L, Zhang H, Miller N, McCready DR, Lockwood G, Egan SE (2005) High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 15:8530–8537CrossRef

33.

Santagata S et al (2004) JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 64(19):6854–6857PubMedCrossRef

34.

Kim SJ et al (2015) Activation of nuclear PTEN by inhibition of notch signaling induces G2/M cell cycle arrest in gastric cancer. Oncogene. doi:10.1038/onc.2015.80

35.

Mulligan P et al (2011) A SIRT1-LSD1 corepressor complex regulates notch target gene expression and development. Mol Cell 42(5):689–699PubMedCentralPubMedCrossRef

36.

King IN et al (2006) Hrt and Hes negatively regulate Notch signaling through interactions with RBP-Jkappa. Biochem Biophys Res Commun 345(1):446–452PubMedCrossRef

37.

Ou-Yang HF et al (2009) Notch signaling regulates the FOXP3 promoter through RBP-J- and Hes1-dependent mechanisms. Mol Cell Biochem 320(1–2):109–114PubMedCrossRef

38.

Fortini ME (2002) [gamma]-Secretase-mediated proteolysis in cell-surface-receptor signalling. Nat Rev Mol Cell Biol 3(9):673–684PubMedCrossRef

39.

Langlois B et al (2010) LRP-1 promotes cancer cell invasion by supporting ERK and inhibiting JNK signaling pathways. PLoS One 5(7):e11584PubMedCentralPubMedCrossRef

40.

Orian-Rousseau V (2010) CD44, a therapeutic target for metastasising tumours. Eur J Cancer 46(7):1271–1277PubMedCrossRef

41.

Cecilia Sahlgren MVG, Jin S, Poellinger L, Lendahl U (2008) Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci 105:6392–6397PubMedCentralPubMedCrossRef

Titel: Targeting Notch signaling by γ-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer
verfasst von: Hyun-Woo Lee
Seok-Jun Kim
Il Ju Choi
Jaewhan Song
Kyung-Hee Chun
Publikationsdatum: 01.08.2015
Verlag: Springer Netherlands
Erschienen in: Clinical & Experimental Metastasis / Ausgabe 6/2015
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-015-9730-5

Springer Medizin

Targeting Notch signaling by γ-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2015

Eight proteins play critical roles in RCC with bone metastasis via mitochondrial dysfunction

Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR

MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer

Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma

Dissemination via the lymphatic or angiogenic route impacts the pathology, microenvironment and hypoxia-related drug response of lung metastases

Cadherin-11 regulates the metastasis of Ewing sarcoma cells to bone

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie